Nutra Pharma Corporation (NPHC)

Overview

Nutra Pharma Corp. is a biopharmaceutical company that focuses on the acquisition, licensing, and commercialization of pharmaceutical products and technologies alongside homeopathic and ethical drugs aimed at the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases, primarily within the United States. Established in 2000, the company has its base in Plantation, Florida, and it positions itself strongly in the market through a diverse portfolio of products targeted at dealing with a wide range of conditions and ailments.

Products and Services

- Nyloxin and Nyloxin Extra Strength: These are oral spray and topical gel forms used for treating various types of pain, including lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain. The topical gel specifically addresses joint pain and pains associated with arthritis and repetitive stress. Their formulation aims to provide a non-narcotic pain relief alternative.

- Pet Pain-Away: A homeopathic, non-narcotic, non-addictive, over-the-counter pain reliever developed specifically for treating chronic pain in companion animals. This product signifies the company's extension of its pain management solutions to the veterinary market.

- Luxury Feet: This over-the-counter product is formulated to relieve pain or discomfort associated with wearing high heels and stilettos, showcasing the company's niche focus on specific pain relief areas.

- Nyloxin Military Strength: Tailored for the United States Military and Veteran's Administration, this product underscores the company's commitment to providing potent pain management solutions for military personnel and veterans.

- Equine Pain-Away: An over-the-counter topical pain reliever designed to alleviate pain in horses, expanding the company's reach into the equine market with a specific focus on addressing their unique pain management needs.

- RPI-78M: Currently under development, this product targets neurological and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis, indicating the company's ongoing research and commitment to addressing complex health conditions.

- RPI-MN: This investigational product is aimed at treating viral diseases like human immunodeficiency virus/AIDS and herpes, in addition to serving general anti-viral applications. It highlights the company's efforts in expanding its pharmaceutical development to the field of infectious diseases.

- RPI-78 for pain and arthritis: Another product in development, focused on addressing the treatment gaps in pain and arthritis, indicative of Nutra Pharma's continuous efforts to innovate in the area of pain management.

- RPI-70 for pain: Also under development, this product is aimed at further expanding the company's portfolio in pain management solutions, reinforcing Nutra Pharma's dedication to innovation in healthcare.